The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate
HFA on small airways compared to Fluticasone propionate powder for inhalation administered
twice daily to poorly controlled asthmatics.
- Poorly controlled asthma;
- Average use of over 2 puffs of albuterol per day in the previous 7 days OR Having
symptoms of asthma on 5 of the last 7 days OR Awakening at night due to asthma at
least once in the previous 7 days OR Having been treated with a course of oral or
intravenous steroids at least once in the last 3 months.
- Subjects receiving escalating doses of immunotherapy, oral immunotherapy or short
course (rush) immunotherapy for rhinitis;
- Requires beta-blockers, MAO inhibitors, tricyclic antidepressants, oral or
- History and/or presence of any non-asthmatic acute or chronic lung disease, including
but not limited to bronchitis, emphysema, active tuberculosis, bronchiectasis or
- History and/or presence of any clinically significant cardiovascular disease,
clinically significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled
diabetes, hyperthyroidism, convulsive disorders, neoplastic disease other than basal
cell carcinoma, and significant psychiatric disease.